Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396952 | 0.90 | ALDH1A1 (0.45) | SMN1; SMN2GAAMEN1KMT2AKDM4E | |
| SCHEMBL1712556 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2GAATDP1MEN1APEX1 | |
| SCHEMBL1712675 | 0.81 | NOTUM (0.47) | L3MBTL1ALDH1A1 | |
| SCHEMBL25512068 | 0.79 | NOTUM (0.31) | SMN1; SMN2 | |
| SCHEMBL1712234 | 0.75 | BCHE (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1712436 | 0.75 | TP53 (0.47) | SMN1; SMN2GAAKDM4EALDH1A1RAB9A | |
| SCHEMBL19362444 | 0.75 | BCHE (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1712685 | 0.75 | BCHE (0.41) | SMN1; SMN2MEN1KMT2ABCHE | |
| SCHEMBL14191824 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2GAATDP1MEN1APEX1 | |
| SCHEMBL16671006 | 0.72 | GAA (0.43) | SMN1; SMN2GAATDP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | claimed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-01 | — | — | US | disclosed |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2019-06-13 | — | — | US | disclosed |
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2345629-B1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-8871934-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8343994-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2345629-A1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100240634-A1 | Fluorene Compound and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | SMN1; SMN2 518/4885GAA 1139/4885TDP1 1371/4885 |
| US-20100240634-A1 | Fluorene Compound and Pharmaceutical Use Thereof | FH, PCK2, PC | SMN1; SMN2 518/4885GAA 1139/4885TDP1 1371/4885 |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | SMN1; SMN2 518/4885GAA 1139/4885TDP1 1371/4885 |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | SMN1; SMN2 518/4885GAA 1139/4885TDP1 1371/4885 |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | SMN1; SMN2 518/4885GAA 1139/4885TDP1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.